Records 1-30 (of 188 Records) |
Query Trace: Myocarditis[original query] |
---|
The role of colchicine in the management of COVID-19: a Meta-analysis. Elshiwy Kholoud, et al. BMC pulmonary medicine 2024 0 0. (1) 190 |
Blood transcriptome analysis uncovered COVID-19-myocarditis crosstalk. Liang Shuang, et al. Microbial pathogenesis 2024 0 0. 106587 |
Pathogenic Variants of Scavenger Receptor CD36 Lead to Decreased Efferocytosis and Predispose to Myocarditis Following Vaccination With Pfizer-BioNTech BNT162b2 Against Coronavirus Infection (COVID-19). Canavati Christina, et al. Circulation 2024 0 0. (3) 270-273 |
COVID-19 mRNA vaccine-related myocarditis: A PRISMA systematic review, imaging approach and differential diagnoses. Yeo Shaun Zhi Jie, et al. Radiology case reports 2024 0 0. (3) 1008-1019 |
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Dayan Gustavo H, et al. The Lancet. Respiratory medicine 2023 0 0. |
Susceptibility of SARS-CoV2 infection in children. Cotugno Nicola, et al. European journal of pediatrics 2023 0 0. |
Eosinophilic myocarditis: from etiology to diagnostics and therapy. Russo Marco, et al. Minerva cardiology and angiology 2023 0 0. |
Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. Abdallah Alami et al. BMJ Open 2023 6 (6) e065687
Seven studies met the inclusion criteria, of which six were included in the quantitative synthesis. Our meta-analysis indicates that within 30-day follow-up period, vaccinated individuals were twice as likely to develop myo/pericarditis in the absence of SARS-CoV-2 infection compared to unvaccinated individuals, with a rate ratio of 2.05 (95% CI 1.49-2.82). Although the absolute number of observed myo/pericarditis cases remains quite low, a higher risk was detected in those who received mRNA COVID-19 vaccinations compared with unvaccinated individuals in the absence of SARS-CoV-2 infection.
|
Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination. Kim Hyeonhui, et al. Scientific reports 2023 0 0. (1) 8926 |
Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5-17. Francisco Tsz Tsun Lai et al. Nature communications 2023 4 (1) 1845
For vaccine recipients with extended intervals [=28 days, adjusted odds ratio 0.718, 95% Confidence Interval: 0.619, 0.833] there was a 29.2%-reduced risk of Covid-19 infection compared to those with regular intervals (21-27 days). If the threshold was set at eight weeks, the risk reduction was estimated at 43.5% (aOR 0.565, 95% CI: 0.456, 0.700). In conclusion, longer dosing intervals for children and adolescents should be considered.
|
Spatial transcriptomic profiling of coronary endothelial cells in SARS-CoV-2 myocarditis. Margaroli Camilla, et al. Frontiers in medicine 2023 0 0. 1118024 |
COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics). Chary Michael, et al. Journal of medical toxicology : official journal of the American College of Medical Toxicology 2023 0 0. |
Comparison of COVID-19 Vaccine-Associated Myocarditis and Viral Myocarditis Pathology. Hamedi Kamron Reza, et al. Vaccines 2023 0 0. (2) |
Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada SA Buchan et al, JAMA Pediatrics, February 27, 2023
In this population-based cohort study of 1.65 million doses of BNT162b2 vaccinations among adolescents in Ontario, Canada, there were 77 adolescents with myocarditis or pericarditis after vaccination and a higher reported incidence among adolescents aged 16 to 17 years vs 12 to 15 years and among those aged 16 to 17 years with a shorter interval between doses. Overall, many of the cases of myocarditis and pericarditis were mild, and the adolescents required either no treatment or were treated conservatively with nonsteroidal anti-inflammatory drugs.
|
T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens. Root-Bernstein Robert, et al. International journal of molecular sciences 2023 0 0. (2) |
Different Types of Myocardial Injury due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant. Moriwaki Keishi, et al. International heart journal 2023 0 0. |
Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study NW Andersson et al, MEDRXIV, January 23, 2023
1,740,417 individuals (mean age 67.8 years, standard deviation 10.7) received a bivalent omicron-containing mRNA-booster vaccine as a fourth dose. Fourth dose vaccination with a bivalent omicron-containing booster did not statistically significantly increase the rate of any of the 27 adverse outcomes within 28 days, nor when analyzed according to age, sex, vaccine type, or using alternative analytical approaches. However, post-hoc analysis detected signals for myocarditis (statistically significantly so in females), although the outcome was very rare and findings were based on few cases.
|
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. Hause Anne M, et al. MMWR. Morbidity and mortality weekly report 2023 0 0. (2) 39-43 |
COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review. Fergie Jaime, et al. Vaccines 2022 0 0. (12) |
A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. Yih W Katherine, et al. Vaccine 2022 0 0. |
Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis. Lai Francisco Tsz Tsun et al. Journal of the American College of Cardiology 2022 12 (24) 2255-2265
A total of 866 patients were included for analysis. Over the follow-up period, 1 death (1.0%) of 104 patients with postvaccination myocarditis and 84 deaths (11.0%) of 762 patients with viral infection–related myocarditis were identified. This study found a significantly lower rate of mortality among individuals with myocarditis after mRNA vaccination compared with those with viral infection–related myocarditis. Prognosis of this iatrogenic condition may be less severe than naturally acquired viral infection–related myocarditis.
|
Severe COVID-19 outcomes in pediatrics: An observational cohort analysis comparing Alpha, Delta, and Omicron variants. Bahl Amit, et al. Lancet regional health. Americas 2022 0 0. 100405 |
Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study Z Naveed et al. CMAJ, November 21, 2022
We conducted an observational study using population health administrative data from the BC COVID-19 Cohort from Dec. 15, 2020, to Mar. 10, 2022. The primary exposure was any dose of an mRNA vaccine against SARS-CoV-2. The primary outcome was incidence of hospital admission or emergency department visit for myocarditis or myopericarditis within 7 and 21 days postvaccination. We observed 99 incident cases of myocarditis within 7 days (0.97 cases per 100 000 vaccine doses; observed v. expected ratio 14.81, and 141 cases within 21 days (1.37 cases per 100 000 vaccine doses; observed v. expected ratio 7.03) postvaccination. Cases of myocarditis per 100 000 vaccine doses were higher for people aged 12–17 years (2.64) and 18–29 years (2.63) than for older age groups, for males compared with females (1.64), for those receiving a second dose compared with a third dose (1.90) and for those who received the mRNA-1273 (Moderna) vaccine compared with the BNT162b2 (Pfizer-BioNTech) vaccine.
|
Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years M Hu et al, MEDRXIV, October 30, 2022
The study included over 3 million enrollees aged 5-17 years with BNT162b2 COVID-19 vaccination through mid-2022 in three commercial claims databases.
Consistent with published literature, our near-real time monitoring identified a signal for only myocarditis/pericarditis following BNT162b2 COVID-19 vaccination in children aged 12-17 years. This method is intended for early detection of safety signals. Our results are reassuring of the safety of the vaccine, and the potential benefits of vaccination outweigh the risks.
|
Machine Learning Analyses Revealed Distinct Arterial Pulse Variability According to Side Effects of Pfizer-BioNTech COVID-19 Vaccine (BNT162b2). Chen Chun-Chao, et al. Journal of clinical medicine 2022 0 0. (20) |
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. Tarasco Erika, et al. Research and practice in thrombosis and haemostasis 2022 0 0. (7) e12814 |
Myocardial Injury and Altered Gene Expression Associated With SARS-CoV-2 Infection or mRNA Vaccination. Altman Natasha L, et al. JACC. Basic to translational science 2022 0 0. |
IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. Thurner Lorenz et al. The New England journal of medicine 2022 9 (16) 1524-1527 |
Myocarditis after BNT162b2 Vaccination in Israeli Adolescents G Witberg et al, NEJM, October 19, 2022
Our study indicates that BNT162b2 vaccine–induced myocarditis in adolescents appears to be a rare adverse event that occurs predominantly in males after the second vaccine dose. The clinical course appears to be mild and benign over a follow-up period of 6 months, and cardiac imaging findings suggest a favorable long-term prognosis.
|
Single-cell sequencing of PBMC characterizes the altered transcriptomic landscape of classical monocytes in BNT162b2-induced myocarditis. Hwang Nahee, et al. Frontiers in immunology 2022 0 0. 979188 |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 19, 2024
- Content source: